Heidelberg Pharma AG

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024

Heidelberg Pharma AG: Walter Miller, buy

Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

Heidelberg Pharma AG: Dr. Georg F. Baur, buy

Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Heidelberg Pharma AG: Walter Miller, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg Pharma AG. …

Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg …

Heidelberg Pharma AG: Dr. Jan Schmidt-Brand, Annahme der Gewährung von 60.000 Aktienoptionen im Rahmen des Aktienoptionsprogramms 2023 für Mitarbeiter und Vorstandsmitglieder der Heidelberg …

Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy

Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023

Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG: Heidelberg Pharma’s Partner Takeda Reached Development Milestone

Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy

Heidelberg Pharma reports on the results of the Annual General Meeting 2023